Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion

Nurix Therapeutics stock trades on Nasdaq under the ticker NRIX with a market capitalization of roughly $1.9 billion, according to recent market data, even as the company continues to report deep operating losses and negative margins across its business lines.Stock Analysis as of 05/08/2026

Over the last 12 months, Nurix Therapeutics posted revenue of about $83.7 million and net losses of approximately $244.8 million, implying a loss per share of roughly $2.97, while its gross margin stood at a negative 259.8% and operating and net profit margins at around -319.3% and -292.5%, respectively.Stock Analysis as of 05/08/2026

As of the latest available figures, Nurix Therapeutics holds about $428.8 million in cash and cash equivalents against roughly $56.5 million in debt, giving the company a net cash position of about $372.3 million, or around $3.67 per share, which may provide runway for ongoing research and development activities.Stock Analysis as of 05/08/2026

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

Nurix Therapeutics: core business model

Nurix Therapeutics is a biotechnology company focused on the discovery and development of targeted protein degraders and other small?molecule therapeutics, primarily for oncology and immune?mediated diseases, using its proprietary DNA?encoded library and E3 ligase expertise to design compounds that can selectively degrade disease?causing proteins.Nurix Therapeutics Investor Relations

The company’s platform aims to expand the range of proteins that can be targeted with small molecules, including those traditionally considered “undruggable,” and it advances internal programs while also entering into collaborations and partnerships with larger pharmaceutical firms to share development costs and potential commercial rewards.Nurix Therapeutics Investor Relations

Because Nurix is still in the pre?commercial stage for most of its pipeline, its business model relies heavily on upfront payments, research funding, and milestone and royalty payments from partners, rather than on product sales, which keeps revenue relatively modest compared with later?stage biotech firms.Nurix Therapeutics SEC filings as of 05/08/2026

Main revenue and product drivers for Nurix Therapeutics

The primary revenue drivers for Nurix Therapeutics are collaboration and licensing agreements with pharmaceutical partners, which typically include upfront payments, research support, and potential milestone payments tied to clinical and regulatory achievements, as well as royalties on any future product sales that may emerge from partnered programs.Nurix Therapeutics SEC filings as of 05/08/2026

Within its internal pipeline, Nurix is advancing targeted protein degraders and other small?molecule candidates in oncology and immune?mediated diseases, with several programs in early? to mid?stage clinical development; successful progression of these assets through clinical trials and eventual regulatory approval could materially increase future revenue and valuation, but also carries substantial scientific and regulatory risk.Nurix Therapeutics Investor Relations

For US investors, Nurix Therapeutics offers exposure to a high?risk, high?potential segment of the biotech sector, where value is largely driven by clinical data readouts, partnership announcements, and regulatory decisions rather than by current earnings, and where the company’s net cash position and ongoing financing capacity are key indicators of its ability to fund development through potential value?inflection events.Stock Analysis as of 05/08/2026

Conclusion

Nurix Therapeutics stock trades on Nasdaq with a market cap of about $1.9 billion, reflecting investor expectations around its targeted protein degrader platform and pipeline, even though the company currently reports substantial operating losses and negative margins.Stock Analysis as of 05/08/2026

The firm’s net cash position of more than $370 million provides a buffer to fund ongoing research and clinical development, but future value will depend heavily on clinical trial outcomes, partnership activity, and potential regulatory approvals, all of which carry significant uncertainty.Stock Analysis as of 05/08/2026

For US investors, Nurix Therapeutics represents a speculative biotech exposure where long?term upside is tied to successful drug development rather than current profitability, and where careful attention to cash burn, pipeline progress, and external financing needs is essential.Nurix Therapeutics SEC filings as of 05/08/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.